Hepatitis Treatment News
A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis Treatment News


July 30, 2014
AbbVie’s Hep C Regimen Is Safe With Opioid Replacement Therapy
AbbVie’s “3D” hepatitis C regimen is safe for use with opioid replacement therapy to treat drug addiction.
July 28, 2014
AbbVie’s '3D' Regimen Shows Promise in Those With Hep C & HIV
AbbVie’s “3D” regimen has shown high cure rates in treating genotype 1 of hepatitis C among those coinfected with HIV, both with and without cirrhosis.
July 23, 2014
Young Drug Users at Especially High Risk of HIV and Hep C
Over half of young injection drug users in the United States share syringes and about four in five report having sex without a condom.
Gilead Reaps $3.48 Billion in Second Quarter Sovaldi Sales
With $3.48 billion in sales of the hepatitis C drug Sovaldi, Gilead Sciences reported a second-quarter revenue of $6.53 billion.
July 22, 2014
Sovaldi and Ribavirin Cure High Rates of Those With HIV & Hep C
Sovaldi (sofosbuvir) and ribavirin cured between 84 percent and 91 percent of people coinfected with HIV and genotypes 1 through 4 of hepatitis C.
July 21, 2014
Just 9 Percent of Americans With Hep C Have Been Cured
Only half of Americans living with hepatitis C are aware of their infection, and just 9 percent of the total have been cured of the virus.
July 17, 2014
People With Both HIV & Hep C Have Raised Risk of Bone Loss
People coinfected with HIV and hepatitis C have a higher risk of osteoporosis and bone fracture than those who are infected with just HIV.
July 16, 2014
FDA Grants 'Priority Review' to Olysio & Sovaldi Hep C Combo
The FDA has granted priority review status to the supplemental New Drug Application for Olysio and Sovaldi to treat genotype 1 of hepatitis C.
July 14, 2014
Methadone Users Willing to Undergo Hepatitis C Treatment
A sizable majority of people with hepatitis C at a New York City methadone clinic told researchers they were willing to receive treatment for the virus.
July 09, 2014
Bristol-Myers Squibb Receives Japanese Approval for Hep C Regimen
Japanese health authorities have approved Bristol-Myers Squibb’s Daklinza (daclatasvir) and Sunvepra (asunaprevir) to treat genotype 1 of hepatitis C.
July 07, 2014
Boehringer Ingelheim Ends Development of Hep C Drug
The German pharmaceutical company Boehringer Ingelheim has ceased development of its investigatory hepatitis C drug faldaprevir.
July 02, 2014
Hep C Decays Faster in Blood Than in the Liver During Treatment
The first study to track in real time the decay of hepatitis C has found that the virus breaks down more quickly in the blood than in the liver.
Archives
   

July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
January 2008


Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Are you planning to do anything for World Hepatitis Day on July 28?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.